NEWS:
Pearls of Bioequivalence & Biopharmaceutics Award 2026
Die als gemeinnützig anerkannte Stiftung Frankfurt Foundation Quality of Medicines (FFQM) engagiert sich für die Förderung von Forschungsaktivitäten, die dazu beitragen, die Qualität von Arzneimitteln in Deutschland zu sichern und ggf. weiter zu optimieren, auch wenn deren Herstellung außerhalb des Landes erfolgt. Zentrales Anliegen ist dabei die Erforschung neuer Verfahren sowie die Implementierung innovativer Technologien und Standardisierungsansätze, einschließlich der kritischen Bewertung von bereits etablierten Konzepten zur Qualitätssicherung.
Gemeinsam mit der European Federation for Pharmaceutical Sciences (EUFEPS) wird alle zwei Jahre der Pearls of Bioequivalence & Biopharmaceutics Award verliehen. Mit diesem Preis (dotiert mit 2.000 €) werden herausragende Arbeiten in den Bereichen Biopharmazie, Bioäquivalenz und innovative Arzneistoff-Freisetzungssysteme gewürdigt.
Weitere Informationen zur Ausschreibung finden Sie auf der Website von EUFEPS:
Zur Ausschreibung
Wir laden alle Forschenden ein, sich mit ihren Arbeiten zu bewerben oder diese Information an geeignete Kolleginnen und Kollegen weiterzugeben.
The Frankfurt Foundation Quality of Medicines (FFQM), recognized as a non-profit organization, is committed to promoting research activities that contribute to ensuring and, where possible, further improving the quality of medicines in Germany—even if they are manufactured abroad. Its central focus is on the development of new methods as well as the implementation of innovative technologies and standardization approaches, including the critical evaluation of already established quality assurance concepts.
Together with the European Federation for Pharmaceutical Sciences (EUFEPS), the foundation awards the Pearls of Bioequivalence & Biopharmaceutics Award every two years. This prize (endowed with €2,000) honors outstanding work in the fields of biopharmaceutics, bioequivalence, and innovative drug delivery systems.
More information about the call for applications can be found on the EUFEPS website:
[Link to the call]
We invite all researchers to apply with their work or to share this information with suitable colleagues.
Symposium "Advances in Predictive Biopharmaceutics, Drug Product Quality and Patient Benefit" in Mainz!
On July 11, 2025, the symposium “Advances in Predictive Biopharmaceutics, Drug Product Quality and Patient Benefit” took place in Mainz.
The event brought together leading experts in the field of biopharmaceutics and provided a valuable platform for scientific exchange and discussion of current developments. A special highlight was the presentation of the 5th Lifetime Achievement Award of the Frankfurt Foundation Quality of Medicines (FFQM) to Professor Gordon L. Amidon in recognition of his outstanding contributions to pharmaceutical research.
We would like to thank all participants and contributors who made this day an inspiring and successful event!
A special thank you goes to all lectureres for sharing their expertise and valuable insights:
- Prof. Paulo Paixão, University of Lisbon, Portugal
- Prof. Hans Lennernäs, University of Uppsala, Sweden
- Prof. Marival Bermejo, University Miguel Hernández de Elche, Alicante, Spain
- Prof. Shinji Yamashita, Ritsumeikan University, Japan
- Prof. Peter Langguth, Gutenberg University Mainz, Germany
- Prof. Werner Weitschies, University of Greifswald, Germany
- Prof. Dagmar Fischer, University of Erlangen, Germany
- Prof. Gordon L. Amidon, University of Michigan, USA
DPhG-FFQM Prize for the Promotion of Drug Quality 2023 awarded to Jonas and Luise
The winners of this year’s prize for promoting drug quality are Sophie Luise Meiser and Jonas Pielenhofer from the working group of Prof. Dr. Peter Langguth, Institute for Biopharmacy and Pharmaceutical Technology at Johannes Gutenberg University, Mainz. Both submitted work in the area of „Quality-by-Design (QbD), Nanotechnology / Clinical Pharmacy“, which was carried out by an interdisciplinary research group.
Pielenhofer accepted the award at the DPhG annual conference in Tübingen on behalf of those involved in the project.
More information can be found here
‘X-ray vision’ for investigation of mRNA nanomedicines
Together with colleagues from EMBL Hamburg, Postnova Analytics GmbH, and BioNTech SE we have developed a new method to investigate mRNA-containing nanoparticles and other pharmaceutical nanoparticle products. The method gives direct and quantitative information on how many particles of each size are in the product, as well as their structure, composition, and many other properties which are key for ensuring consistent product quality and effectiveness. The new approach can be easily adapted by the pharmaceutical industry and academia, and is expected to enable faster and more efficient development of new nanomedicines comprising mRNA and other drug substances in the future. On the picture, Christoph and Bastian together with EMBL staff scientist Melissa Graewert are performing measurements of RNA using small-angle X-ray scattering at the EMBL beamline P12 in Hamburg. (Credit: Dorota Badowska/EMBL)
More information can be found here.
Recent Publications:
